GlassScriptPhysician profile
Lisa S Kellogg
NPI 1720034127
$16,097.31
in general payments reported to CMS, 2019-2025
67 companies · $2,664 in 2025
The $2,664 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $787 · 2021: $2,193 · 2022: $2,736 · 2023: $2,983 · 2024: $2,862 · 2025: $2,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,333 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,332.66 |
| Education | $176.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,817.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,871.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,442.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,162.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,154.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $886.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $792.76 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $713.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.05 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $572.41 | 2019-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $261.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $217.81 | 2021-2025 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $195.99 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $183.91 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $175.32 | 2019-2023 | Trintellix |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.